S.42. Potential Role for Serum Soluble CD200 in Human Chronic Lymphocytic Leukemia (original) (raw)
Advances in Therapy, 2007
Investigators in this study explored levels of soluble CD27 (sCD27), interleukin (IL)-8, and IL-10 in B-cell chronic lymphocytic leukemia (B-CLL), and the correlation of these levels with disease stage and prognosis. Plasma IL-8, IL-10, and sCD27 levels were assessed with enzyme-linked immunosorbent assay tests in 22 healthy donors and 70 patients with B-CLL (49 men and 21 women). Mean patient age was 61.57 y (range, 44-75 y). Mean healthy donor age was 62.09 y (range, 40-72 y). In the study group, mean values were as follows: plasma IL-8, 284.758 pg/mL (0-1000 pg/mL); plasma IL-10, 26.152 pg/mL (0-100 pg/mL); sCD27, 731.357 U/mL (139.9-1000 U/mL); white blood cell count, 59.9 × 10 9 /L (0.8-250.0 × 10 9 /L); hemoglobin count, 11.2 g/dL (5.0-16.2 g/dL); platelet count, 162.5 × 10 9 /L (29.8-317 × 10 9 /L); B 2 microglobulin (B 2 M) 3350.2 mg/L (274.7-7499.9 mg/L); CD38, 19.5%; and lactate dehydrogenase (count, 497.5 U/L (263.0-1507 U/L). Patients represented all Rai stages, with 22.9% at stage 0, 11.4% at stage I, 11.4% at stage II, 41.4% at stage III, and 12.9% at stage IV. Plasma levels of IL-8, IL-10, and sCD27 were correlated between study and control groups; significantly higher IL-8 (P=.001) and sCD27 (P=.000) levels were found, but the IL-10 level was not significant (P=.139). Plasma IL-10 (P=.01) and sCD27 (P=.008) were positively correlated with Rai stage, but IL-8 was not (P=.146). Levels of sCD27 were significantly correlated with values for B 2 M (P=.000), hemoglobin (P=.028), lactate dehydrogenase (P=.001), CD19 (P=.03), and IL-10 (P=.000). IL-8 was significantly correlated with white blood cell (P=.000) count, and CD38 (P=.001) and CD5 (P=.006) levels. IL-10 was 29
2015
Objective: To determine the clinical and epidemiological and laboratory characteristics of Chronic-B Lymphocytic Leukemia (B-CLL) and other chronic-B lymphoproliferative malignancies (B-CLM), including the expression of CD200. Methods: A retrospective and descriptive study of the case series type conducted at the Foundation HEMOPE with adults of both sexes diagnosed with B-CLL and other B-CLMs. Results: 95 patients were assessed, of whom 64 had B-CLL and 31 other B-CLMs. The average age was 70.40 years in BCLL and 61.80 years in the other B-CLMs. Adenomegaly was more frequent in patients with B-CLL, whereas splenomegaly and B symptoms were more frequently observed in other B-CLMs. In patients with B-CLL, the average of leukocytes was 82,607/ul (80.26% lymphocytes and 13.33% neutrophils), whereas in other B-CLMs, the average of leukocytes was 63,614 / ul (70.32% lymphocytes and14.67% neutrophils) but this was statistically significant only in the observation of greater lymphocytosis ...
Th17/IL-17A Might Play a Protective Role in Chronic Lymphocytic Leukemia Immunity
PLoS ONE, 2013
Th17 cells, a recently discovered subset of T helper cells that secrete IL-17A, can affect the inflammation process autoimmune and cancer diseases development. The purpose of this study was to evaluate the role of Th17 cells and IL17A in biology of CLL. The study group included 294 untreated CLL patients in different clinical stages. Here, we show that higher Th17 and IL-17A values were associated with less advanced clinical stage of CLL. Th17 cells' percentages in PB were lower in patients who died due to CLL during follow-up due to CLL (as compared to surviving patients) and in patients responding to first-line therapy with fludarabine-based regimens (as compared to non-responders). IL-17A inversely correlated with the time from CLL diagnosis to the start of therapy and was lower in patients who required treatment during follow-up. Th-17 and IL-17A values were lower in patients with adverse prognostic factors (17p and 11q deletion, CD38 and ZAP-70 expression). CLL patients with detectable IL-17A mRNA in T cells were in Rai Stage 0 and negative for both ZAP-70 and CD38 expression. Th17 percentages positively correlated with iNKT and adversely with Treg cells. The results of this study suggest that Th17 may play a beneficial role in CLL immunity.
International journal of health sciences
B cell chronic lymphocytic leukemia (B-CLL) is the highest incidence of lymphoproliferative malignant disease in most adults in the western world. Due to the importance of the pathogenicity and risk factors of this disease, this study was designed to analyze the expression the pattern of CD200 by flow cytometer immunophenotyping (FCI) and the association between this marker and some clinical features and oxidant-antioxidant status in B-chronic lymphocytic leukemia patients. This study was conducted on 60 newly diagnostic patients with B-CLL and 30 apparently healthy individuals as control group. The socio-demographic information including (age and sex) and clinical data were also collected in period 20 February 2021 to 25 December. The result of statistical analysis of the present study showed that out of the 60 patients, 39 were male and 21 females, with 30 controls (12 males and 18 females). The mean age of adults patients was (64.04 ± 5.6) years, and the adults control mean age o...
Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia
Blood, 1996
Prognosis of B-cell chronic lymphocytic leukemia (CLL) is based on clinical staging whose limitation is the failure to assess whether the disease will progress or remain stable in early stage (Binet A, or Rai 0, I, II) patients. We previously reported that soluble CD23 (sCD23), a protein derived from the B-cell membrane CD23 Ag, is selectively elevated in the serum of CLL patients. This prospective study assessed the predictive value of serum sCD23 level measured at study entry on the overall survival of all CLL patients and on disease progression of stage Binet A patients. Prognostic value of repeated measurements of sCD23 over time in stage A patients was also analyzed. One hundred fifty-three CLL patients were prospectively followed with a median follow-up of 78 months. Eight clinical or biological parameters were collected from the date of the first sCD23 measurement. At study entry, by Cox model, Binet staging (P = .0001) and serum sCD23 level (P = .03) appeared as prognostic f...
International Journal of Clinical & Laboratory Research, 1995
One hundred and twenty-four sera from patients with various leukemic B-cell chronic lymphoproliferative diseases were investigated at diagnosis by ELISA for their soluble CD23 content. Immunophenotyping was carried out in all patients, and in a selected subset the mean number of membrane-bound CD23 molecules per cell was also investigated. Seventy-three patients had typical B chronic lymphocytic leukemia, 41 leukemic B-cell disorders with atypical morphological and/or immunophenotypic features, 5 had low-grade follicular cell lymphoma in the leukemic phase, and 5 had splenic lymphoma with villous lymphocytes. Soluble CD23 levels were significantly higher than in normal sera (mean_+SD: typical B chronic lymphocytic leukemia 3,650_+4,654 U/ml, atypical B chronic lymphocytic leukemia 3,440_+4,671 U/ml, follicular cell lymphoma 3,200_+ 1,511 U/ml, splenic lymphoma with villous lymphocytes 8,236_+ 7,294 U/ml, controls 137_+128 U/ml; P<0.001). More advanced Rai's stages were related to higher soluble CD23 levels (P<0.01), both in typical and atypical B chronic lymphocytic leukemias, the highest levels and the best correlation with the absolute number of circulating CDI9 + cells (r=0.50) being observed in the typical form. The number of membrane-bound CD23 molecules per cell was significantly higher in typical than in atypical B chronic lymphocytic leukemias (mean number 156,727_+94,668 vs. 12,010_+ 10,643, P<0.001). Our data suggest that soluble CD23 levels correlate with the clinical and biological features of leukemic B-cell lymphoproliferative disorders.
Cytokine, 2013
Interleukin-21 (IL21) plays an important role in B-cell proliferation, survival and differentiation. Contrary to its stimulatory effect in normal B cells, it has been shown that it induces pro-apoptotic effect in leukemic B cells from CLL patients. Little is known regarding the biological function of IL21 in leukemic B cells from progressive and non-progressive CLL patients. In the present study, the proliferative effect of IL21 in combination with TLR9 agonist (CpG) was investigated in B cells isolated from 24 CLL patients and eight normal subjects by radioactive thymidine incorporation assay. B cells were enriched from peripheral blood mononuclear cells by negative selection using magnetic beads (MACS) and immunophenotyped by flow cytometry. Our results showed that IL21 enhanced the proliferative effects of CpG in both normal and leukemic B cells, though no significant differences were observed between CLL patients and healthy controls. Comparison between different subsets of patients revealed that while the combination of IL21 and CpG significantly inhibited the proliferation of B cells from progressive compared to nonprogressive patients (p = 0.001), it enhanced proliferation of leukemic B cells from IGHV mutated compared to unmutated patients (p = 0.001). The inhibitory effect of IL21 on proliferation of normal and leukemic cells was found to be apoptosis-independent. Our findings suggest differential effects of IL21 in different subsets of CLL patients and suggest its potential therapeutic implication in patients with a more progressive disease.